JP2020515578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515578A5 JP2020515578A5 JP2019553113A JP2019553113A JP2020515578A5 JP 2020515578 A5 JP2020515578 A5 JP 2020515578A5 JP 2019553113 A JP2019553113 A JP 2019553113A JP 2019553113 A JP2019553113 A JP 2019553113A JP 2020515578 A5 JP2020515578 A5 JP 2020515578A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- antibody
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 17
- 239000011780 sodium chloride Substances 0.000 claims 17
- 239000000611 antibody drug conjugate Substances 0.000 claims 16
- 108091008116 antibody drug conjugates Proteins 0.000 claims 16
- 108090001123 antibodies Proteins 0.000 claims 9
- 102000004965 antibodies Human genes 0.000 claims 9
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 9
- 229940121372 histone deacetylase inhibitors Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drugs Drugs 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- 108010022830 Cetuximab Proteins 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 206010027457 Metastases to liver Diseases 0.000 claims 1
- 208000009091 Myxoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010061219 Panitumumab Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 108010010691 Trastuzumab Proteins 0.000 claims 1
- 230000003187 abdominal Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
- 0 *N(C(CC1)=O)C1=O Chemical compound *N(C(CC1)=O)C1=O 0.000 description 4
- XJLIZVNBNOGQIZ-UHFFFAOYSA-N CC(C)(CCOC(C)(C)CCN(C(C=C1)=O)C1=O)C(NCCNC)=O Chemical compound CC(C)(CCOC(C)(C)CCN(C(C=C1)=O)C1=O)C(NCCNC)=O XJLIZVNBNOGQIZ-UHFFFAOYSA-N 0.000 description 1
- QXYUPYCLYVKFML-UHFFFAOYSA-N CC(C)NCCN(C(C(Br)=C1Br)=O)C1=O Chemical compound CC(C)NCCN(C(C(Br)=C1Br)=O)C1=O QXYUPYCLYVKFML-UHFFFAOYSA-N 0.000 description 1
- CEKBIZXSKXIHKR-QWRGUYRKSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC CEKBIZXSKXIHKR-QWRGUYRKSA-N 0.000 description 1
- BYTQYJBXDFBAMS-UHFFFAOYSA-N CCN(C1OC1C(C)C1)C1=O Chemical compound CCN(C1OC1C(C)C1)C1=O BYTQYJBXDFBAMS-UHFFFAOYSA-N 0.000 description 1
- FEPCRJPVYFSZFH-UHFFFAOYSA-N CNCCN(C(C=C1)=O)C1=O Chemical compound CNCCN(C(C=C1)=O)C1=O FEPCRJPVYFSZFH-UHFFFAOYSA-N 0.000 description 1
- ZYPSDIUSNSIUEG-UHFFFAOYSA-N CNCCN(C(CC1=C)=O)C1=O Chemical compound CNCCN(C(CC1=C)=O)C1=O ZYPSDIUSNSIUEG-UHFFFAOYSA-N 0.000 description 1
- LDNWXFQQLQTQKU-UHFFFAOYSA-N CNCCNC(C(CC(O)=O)=C)=O Chemical compound CNCCNC(C(CC(O)=O)=C)=O LDNWXFQQLQTQKU-UHFFFAOYSA-N 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N COc(cc1)ccc1[N+]([O-])=O Chemical compound COc(cc1)ccc1[N+]([O-])=O BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- CVYZVNVPQRKDLW-UHFFFAOYSA-N COc(ccc([N+]([O-])=O)c1)c1[N+]([O-])=O Chemical compound COc(ccc([N+]([O-])=O)c1)c1[N+]([O-])=O CVYZVNVPQRKDLW-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N CSc1ccccc1 Chemical compound CSc1ccccc1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163065.0A EP3381474A1 (en) | 2017-03-27 | 2017-03-27 | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
| EP17163065.0 | 2017-03-27 | ||
| PCT/EP2018/057744 WO2018178060A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515578A JP2020515578A (ja) | 2020-05-28 |
| JP2020515578A5 true JP2020515578A5 (US07585860-20090908-C00112.png) | 2021-02-12 |
Family
ID=58448395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553113A Pending JP2020515578A (ja) | 2017-03-27 | 2018-03-27 | Ｈｄａｃ阻害剤系抗体薬物コンジュゲート（ａｄｃ）及び治療における使用 |
Country Status (15)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220133892A1 (en) * | 2019-02-25 | 2022-05-05 | Emory University | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions |
| US20230257366A1 (en) * | 2020-07-20 | 2023-08-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
| CN112430229B (zh) * | 2020-11-24 | 2023-03-21 | 福建医科大学 | 一种靶向降解parp蛋白的化合物及其制备方法与应用 |
| CN113292465B (zh) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | 一种半胱氨酸衍生物及其合成方法、应用 |
| WO2023059581A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| CN118085013A (zh) * | 2022-11-25 | 2024-05-28 | 成都微芯新域生物技术有限公司 | 一种连接子、含连接子的抗体药物偶联物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1993146A (zh) * | 2004-06-01 | 2007-07-04 | 健泰科生物技术公司 | 抗体－药物偶联物和方法 |
| EP2361619A1 (en) * | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| UA108598C2 (xx) * | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| US20170319709A1 (en) * | 2013-07-05 | 2017-11-09 | Formation Biologics Inc. | Egfr antibody conjugates |
| CN106459205B (zh) * | 2014-04-11 | 2021-04-09 | 免疫医疗有限责任公司 | 包含半胱氨酸工程化抗体的轭合化合物 |
-
2017
- 2017-03-27 EP EP17163065.0A patent/EP3381474A1/en not_active Withdrawn
-
2018
- 2018-03-27 MX MX2019011492A patent/MX2019011492A/es unknown
- 2018-03-27 KR KR1020197028286A patent/KR20190126824A/ko not_active Application Discontinuation
- 2018-03-27 US US16/492,355 patent/US20210128740A1/en not_active Abandoned
- 2018-03-27 TN TNP/2019/000187A patent/TN2019000187A1/en unknown
- 2018-03-27 UA UAA201909898A patent/UA125311C2/uk unknown
- 2018-03-27 EA EA201991985A patent/EA201991985A1/ru unknown
- 2018-03-27 CN CN201880022128.4A patent/CN110475572A/zh active Pending
- 2018-03-27 AU AU2018241840A patent/AU2018241840A1/en active Pending
- 2018-03-27 SG SG10202109654S patent/SG10202109654SA/en unknown
- 2018-03-27 BR BR112019013449A patent/BR112019013449A2/pt not_active IP Right Cessation
- 2018-03-27 SG SG11201906543RA patent/SG11201906543RA/en unknown
- 2018-03-27 CA CA3047359A patent/CA3047359A1/en active Pending
- 2018-03-27 EP EP18712246.0A patent/EP3600444A1/en not_active Withdrawn
- 2018-03-27 WO PCT/EP2018/057744 patent/WO2018178060A1/en unknown
- 2018-03-27 JP JP2019553113A patent/JP2020515578A/ja active Pending
-
2019
- 2019-08-21 IL IL26882119A patent/IL268821A/en unknown
